-
Expand what’s possible for your API
Our ambient drying technology LaminarPace opens up unique thermostable formulation possibilities for next-generation biomolecules - from vaccines to protein therapeutics.
-
We’re drying biologics
Ambient drying is a new way of drying biologics that eliminates the need for elevated temperatures. Our unique system LaminarPace uses mass transfer not heat transfer to formulate biomolecules as thermostable powders without heat stress.
-
Your partner for ambient drying
Ziccum runs Feasibility and Evaluation studies as part of a formal collaboration agreement for a wide range of clients from Big Pharma development teams and Biotech startups to university departments.
-
High yield, low cost, thermostable
From mRNA and proteins to peptides, antibodies and lipids, LaminarPace can formulate costly biomolecule materials with a process yield of typically 80% . Explore the five major benefits of ambient drying.
-
Moving beyond injectables
In 2022, the world’s three best-selling drugs were all injectable biologics requiring costly administration. LaminarPace’s particle engineering capabilities enable the formulation of fast-dissolving powder biologics for novel administration routes beyond injection.
-
A new unit of pharmaceutical production
LaminarPace is being developed to be integrated into the pharmaceutical manufacturing process as a complete unit of production. We are using 3D digital modeling to drive industrial development, tech transfer and efficiencies of scale.
Meet Ziccum. Our team combines decades of pharmaceutical experience with extensive expertise in formulation, biochemistry, process engineering and more.
We dry biologics
Ziccum's unique ambient drying system LaminarPace is a new way of drying biologics. It eliminates heat stress, heat degradation and the need for elevated temperatures. Unlike other pharmaceutical drying systems, LaminarPace uses Mass Transfer, not Heat Transfer, to dry delicate biologics from vaccines to protein therapeutics as particle-engineered powders that are thermostable and also highly suitable for novel administration routes.
What is LaminarPace?
Ziccum’s ambient drying technology LaminarPace has successfully dried biomolecules - from mRNA, proteins, vaccines and peptides to antibodies and lipids - as thermostable, particle-engineered powders.
Expanding possibilities for next-generation vaccines and biologics
Our unique ambient drying technology, LaminarPace, dries next-generation vaccines and biologics as particle-engineered powders that are thermostable and also highly suited for novel administration routes.
Explore our Business Model
Ziccum offers licenses and tech transfers to vaccine and biotherapeutics companies based on our patent portfolio and continuous technology development. Our overall objective is to enter into one or more license agreements with one or more major pharmaceutical companies.
Invest in innovation
Innovation in vaccination formulation is growing. Interested in investing? In our Investors section you can Subscribe to regular news updates and explore our Business Model, Portfolio Overview and how ambient drynig can help drive sustainability in vaccine production.
Contact us
Whether you have an enquiry on your development project, are interested in a career in Ziccum, or have a technical question – contact us here.